Oramed Pharmaceuticals
ORMP
61 hedge funds and large institutions have $9.3M invested in Oramed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 29 closing their positions.
288% more call options, than puts
Call options by funds: $314K | Put options by funds: $81K
1.51% more ownership
Funds ownership: 9.21% → 10.72% (+1.5%)
21% less funds holding
Funds holding: 77 → 61 (-16)
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
57% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 21
78% less capital invested
Capital invested by funds: $43.2M → $9.3M (-$33.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$4.31M |
| 2 |
Two Sigma Investments
New York
|
+$1.61M |
| 3 |
Two Sigma Advisers
New York
|
+$613K |
| 4 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
+$361K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$300K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LC
Lindbrook Capital
Calabasas,
California
|
-$4.61M |
| 2 |
Millennium Management
New York
|
-$1.03M |
| 3 |
JP Morgan Chase
New York
|
-$732K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$680K |
| 5 |
Man Group
London,
United Kingdom
|
-$665K |
ORMP Hedge Fund Activity: Q1 2023 in Review
61 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2023, worth a combined $9.3M — down 78% from $43.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ORMP and 15 opened new positions — a net loss of 14 holders — while 21 trimmed existing stakes and 9 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $4.31M. The largest seller was Lindbrook Capital, exiting entirely with an estimated $4.61M sold.
- 61 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2023, down from 77 in Q4 2022.
- Funds reported $9.3M of Oramed Pharmaceuticals stock for Q1 2023, down 78% quarter-over-quarter.
- 15 funds opened new Oramed Pharmaceuticals positions in Q1 2023 and 29 closed out, a net change of -14 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2023 was BML Capital Management, an estimated $4.31M added.
- The largest Oramed Pharmaceuticals seller in Q1 2023 was Lindbrook Capital, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2023.